Respiratory medicine and thoracic surgery by Alpers, J. et al.
PUBLISHED VERSION  
 
Alpers, John H.; Cranston, Josephine Margaret; Crockett, Alan Joseph  
Respiratory medicine and thoracic surgery Medical Journal of Australia, 2002; 176 
(1):40 
 
This article is available from the Medical Journal of Australia at:  
 
 








This document has been archived with permission from the editor of the Medical 










40 MJA Vol 176 7 January 2002
UPDATES IN MEDICINE
The Medical Journal of Australia ISSN: 0025-729X 7 January 2002 176 1 40
©The Medical Journal of Australia 2001 www.mja.com.au
UPDATES IN MEDICINE
NEW ADVANCES HAVE REINFORCED our understanding of
respiratory disease as a complex interaction between environ-
ment, genetic predisposition and host responses.1 We
describe recent advances in diseases that are a major cause of
morbidity and mortality.
Prevention. Smoking cessation, pollution control, vaccina-
tion, medical review and education represent important
advances in respiratory disease prevention. Effective interven-
tions for nicotine addiction include replacement therapy (eg,
transdermal patches, nasal spray, gum) and antidepressants
(bupropion, nortriptyline).2 Both are efficacious when used
correctly, but more so in conjunction with behavioural modi-
fication.2,3
Epidemiological studies have identified the importance of
reducing exposure to occupational dusts and chemicals, air
pollution and passive smoking.1,2 Reduction of pollution has
required public policy, altered workplace practices and indi-
vidual protective strategies.
The characterisation of the genetic basis of disorders such
as cystic fibrosis (CF) and a1-antitrypsin deficiency has made
a major impact on their prevention by identifying at-risk
individuals.1,2
The emergence of multidrug-resistant strains of Streptococ-
cus pneumoniae has led to the development of a 23-valent
pneumococcal vaccine, effective in preventing pneumococcal
bacteraemia and pneumonia in high-risk patients.4 Influenza
vaccination appears to reduce serious illness and death in
chronic obstructive pulmonary disease (COPD).2
Diagnosis. Innovative technologies have enabled the rapid
diagnosis of many respiratory disorders.1 Computed tomogra-
phy (thin-section and spiral) is used to diagnose lung cancer,
pulmonary embolus and to assess emphysema.1 The detection
of bacterial DNA in clinical samples by polymerase chain
reaction (PCR) permits rapid identification of the infection.
PCR is also being used to monitor viral load (eg, cytomegalo-
virus) in immunosuppressed individuals. Invasive surgical
techniques include video-assisted thoracoscopy, a procedure
with low morbidity, high diagnostic accuracy and short post-
operative recovery time.1
Interventions. Treatment of asthma in high risk patients
should be aligned to the degree of airway inflammation.4
Inhaled anti-inflammatory drugs are effective maintenance
treatment, reducing symptoms and improving quality of
life.3,4 Adding a long-acting b2-agonist to inhaled corticoster-
oids is as effective as increasing the dose of inhaled steroids.4
Combined therapy may have a significant disease-modifying
effect on inflammation and remodelling. Leukotriene modu-
lators may be useful for patients when inhaled corticosteroids
fail to control asthma.4
Treatment of COPD is still controversial. No current ther-
apy modifies the long-term decline in FEV1.2 Bronchodilators
control symptoms,2 and combining a long-acting b2-agonist
and an anticholinergic drug or theophylline may produce
additional benefits in lung function.2,4 Oxygen therapy and
multidisciplinary rehabilitation programs improve survival,
symptoms and quality of life.2 Surgical treatments include lung
volume reduction surgery (LVRS) for regional emphysema,
and bullectomy for giant bullous emphysema.
Randomised controlled trials are being con-
ducted to compare LVRS with optimal medi-
cal therapy,2 but patients at high risk of death
after LVRS have recently been identified. 
No successful medical therapy has been
found to treat interstitial lung disease. How-
ever, one study reported significant improvement after 12
months of treatment with interferon-g1b and corticosteroids
compared with corticosteroids alone.3
Treatments such as laser methods, endobronchial radiation
and airway stents offer palliation for terminal lung cancer.1
The recognition in recent years that mild to moderate
obstructive sleep apnoea is a major risk factor in cardiovascular
morbidity and mortality represents a major advance.
Although S. pneumoniae is the most common pathogen in
cases of community acquired pneumonia, other pathogens, such
as Legionella species, Staphylococcus aureus, Pseudomonas aeru-
ginosa and Mycoplasma pneumoniae, are also implicated.3 Early
therapy with penicillin or third-generation cephalosporin with
a macrolide is important.3
Meta-analysis shows that neuraminidase inhibitors are
effective in preventing influenza A and B and in shortening
the duration of illness.5
The recognition that hyaline membrane disease of the newborn
is caused by a surfactant deficiency and subsequent intra-
tracheal administration of surfactant has been estimated to
save 2000 neonates per year in the United States.1
Advances in surgical technique and perioperative manage-
ment have led to improved survival for patients undergoing
lung transplantation. In carefully selected patients with
advanced lung disease (eg, COPD, CF, ILD or bronchiecta-
sis), lung transplantation has also been reported to improve
quality of life and functional capacity.1,2
Ventilatory support includes both non-invasive negative-
pressure or positive-pressure ventilation and invasive
mechanical ventilation.4 Advances in ventilation have reduced
mortality from respiratory failure resulting from acute respira-
tory distress syndrome, congestive heart failure, asthma and
COPD with acute carbon dioxide retention.1
Conclusion. Increasing understanding of the mechanisms of
respiratory disease, particularly at the cellular and molecular
level, will enable improved diagnosis and treatment. Preven-
tion remains a key strategy.
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